MyoKardia (NASDAQ: MYOK) and UROGEN PHARMA (NASDAQ:URGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for MyoKardia and UROGEN PHARMA, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MyoKardia 0 0 5 0 3.00
UROGEN PHARMA 0 0 4 0 3.00

MyoKardia presently has a consensus target price of $55.00, suggesting a potential upside of 42.30%. UROGEN PHARMA has a consensus target price of $31.33, suggesting a potential downside of 7.27%. Given MyoKardia’s higher possible upside, equities research analysts clearly believe MyoKardia is more favorable than UROGEN PHARMA.

Valuation & Earnings

This table compares MyoKardia and UROGEN PHARMA’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
MyoKardia $39.20 34.98 -$13.15 ($0.69) -56.01
UROGEN PHARMA $17.53 25.08 -$1.94 N/A N/A

UROGEN PHARMA has higher revenue, but lower earnings than MyoKardia.


This table compares MyoKardia and UROGEN PHARMA’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MyoKardia -44.65% -16.35% -12.16%

Institutional and Insider Ownership

43.7% of MyoKardia shares are held by institutional investors. Comparatively, 36.4% of UROGEN PHARMA shares are held by institutional investors. 33.4% of MyoKardia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.


MyoKardia beats UROGEN PHARMA on 6 of the 10 factors compared between the two stocks.

MyoKardia Company Profile

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

UROGEN PHARMA Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with's FREE daily email newsletter.